Cooley Advises Auspex on its Initial Public Offering

San Diego, Calif. – February 24, 2014 – Cooley LLP announced today that it advised Auspex Pharmaceuticals on its $96.6 million IPO. Auspex is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. Orphan Diseases are rare diseases that affect fewer than 200,000 people in the United States and that may often present unmet medical needs. Auspex now trades on the NASDAQ Global Market under the symbol "ASPX."

The Cooley corporate and securities team advising Auspex was led by partner Ken Rollins and included associates James Pennington, Karen Deschaine, Kevin Henderson, Rebecca Jones and Terren O'Connor. Critical support for the offering was provided by partner Natasha Leskovsek (regulatory); associate Megan Arthur (compensation & benefits); and partners Susan Cooper Philpot and Bill Morrow (tax).

This offering follows Cooley's record year in 2013 for capital markets in which the firm advised on 60 public offerings, including 23 IPOs, raising more than $8.4 billion. Year-to-date in 2014, Cooley has advised on 22 completed public offerings, including 12 completed IPOs.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.